This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Enayatolah Niakan, MD; Tulio E. Bertorini, MD; Sergio R. Acchiardo, MD; Mary F. Werner, MD

Arch Neurol. 1981;38(6):378-379.

Abstract
• Because procainamide hydrochloride (Pronestyl) may block neuromuscular transmission (NMT), this drug is contraindicated in cases of myasthenia gravis. Reduction of the safety factor of NMT is also seen in other conditions, including peripheral neuropathies. A patient with uremic peripheral neuropathy in whom myasthenia-like weakness developed during procainamide therapy is described. Procainamide should be given with caution in cases of peripheral neuropathies in which there may be a reduction of the safety factor of NMT.

Author Affiliations
From the Departments of Neurology (Drs Niakan and Bertorini), and Medicine (Drs Acchiardo and Werner), Division of Nephrology, The University of Tennessee Center for the Health Sciences, Memphis. Dr Niakan is a clinical fellow of the Muscular Dystrophy Associations of America Inc.

Footnotes
Accepted for publication Oct 27, 1980.

Reprint requests to Department of Neurology, The University of Tennessee Center for the Health Sciences, 956 Court Ave, Memphis, TN 38163 (Dr Bertorini).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Drugs and Myasthenia Gravis: An Update
Wittbrodt
Arch Intern Med 1997;157:399-408.
ABSTRACT  

Cerebellar Ataxia due to Procainamide Toxicity
Schwartz et al.
Arch Intern Med 1984;144:2260-2261.
ABSTRACT